Study Finds That Use of Psychedelics Decreases Opioid Consumption

New research has found that the use of psychedelic substances such as DMT, mescaline, psilocybin and LSD is linked to a considerable decline in the consumption of opioids. For their study, the researchers analyzed data from cohorts comprised of individuals suffering from substance misuse disorders. These cohorts included more than 200 people who admitted to using psychedelic substances in the last six months while another 1,092 admitted to using opioids.

The researchers found that using psychedelics was linked to a 55% decrease in the daily use of opioids. Their findings were published in the “Journal of International Drug Policy.” It is the first longitudinal study to associate the use of psychedelics with decreased opioid use.

Elena Argento, who is the lead author of the study, stated that their findings aligned with increasing evidence which suggests that the use of psychedelics may be linked to distinguishable decreases in subsequent use of substances, including the use of opioids. The University of British Columbia researcher added that their findings warranted further studies on psychedelic substances as possible treatments for other substance-use disorders.

In their conclusion, the researchers noted that they had discovered that the naturalistic use of psychedelics was independently associated with substantially decreased odds of subsequent everyday use of opioids among a community-based sample of individuals who suffer from substance use disorders.

They argued that more research with longer-term follow up and controlled trials was needed to find out more about the therapeutic potential of psychedelic substances to add to existing interventions for substance-use disorders, especially among diverse populations. In addition to this, they asserted that supplementary qualitative studies would also offer opportunities to better the understanding of the possible psycho-social mechanisms that underpin psychedelic experiences.

A separate study also discovered that when individuals used marijuana along with psychedelic substances, it was linked to higher scores of visual alterations, ego-dissolution and mystical-type experience.

With reference to cannabis, another study published earlier in the year discovered that the use of marijuana was linked to substantial decreases in dependence on prescription drugs such as opioids as well as improved quality of life. The opioid epidemic has claimed a significant number of lives these past few years, with figures showing that in 2019, about 50,000 individuals in the United States died from opioid overdoses.

In addition to this, separate research published in 2020 found that states which had enacted cannabis legalization laws observed prescription rates for opioid use decline by about 20% in comparison to states that still prohibit cannabis use.

Psychedelics have a lot of therapeutic potential, and it is no surprise that companies such as Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are heavily invested in bringing several therapeutic formulations made from psychedelics onto the market.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.